Flow cytometric analysis (Figure 3B-C) showed that the combination treatment of KRAS-ASO-EVs and immR-EVs outperformed all other treatment groups in promoting the infiltration of CD45+ immune cells into cancer spheroids. The gene discussed is KRAS; the disease is cancer.